Semaglutide and tirzepatide share the same kind of side effects — overwhelmingly gastrointestinal, dose-dependent, and worst during dose escalation (semaglutide, a GLP-1 receptor agonist, sold as Ozempic and Wegovy; tirzepatide, a dual GIP/GLP-1 receptor agonist, sold as Mounjaro and Zepbound). Both slow gastric emptying and act on central appetite and nausea pathways, so nausea, vomiting, diarrhea, and constipation dominate both, are usually mild-to-moderate, and tend to ease over time. In the one fair head-to-head obesity trial, overall side-effect rates were similar, with slightly fewer people stopping tirzepatide for side effects. Which one you tolerate better is something only a prescribing clinician can judge. This is general information, not medical advice — talk to your prescriber about your own situation.
The shared side-effect profile
Despite tirzepatide adding GIP activity to the GLP-1 mechanism that semaglutide uses, the two medicines produce the same class of adverse effects. Both act on the GLP-1 receptor, which slows how fast the stomach empties and engages central appetite and nausea pathways. The practical result is that both are gastrointestinal-dominant: the most commonly reported effects are nausea, vomiting, diarrhea, and constipation.
Three patterns hold across the trial evidence for both drugs:
- Dose-dependent. Higher doses tend to bring more GI effects.
- Worst during escalation. Symptoms cluster around starting the medicine and stepping the dose up, then settle.
- Usually mild-to-moderate and self-limiting. For most people these are a nuisance that eases as the body adapts, not a reason to stop.
Tirzepatide's extra GIP activity does not change this overall shape — its adverse-event profile stays GI-dominant and consistent with the class. For more on the symptoms themselves, see our overview of GLP-1 side effects and the detail page on nausea.
Reported side-effect rates, side by side
The table below pulls per-symptom rates from the published obesity trials. Read it as two separate studies placed next to each other, not as a direct contest: the semaglutide figures come from the STEP program and the tirzepatide figures from SURMOUNT-1, which enrolled different populations. (See why these numbers are not apples-to-apples below.)
| Side effect | Semaglutide 2.4 mg (STEP, pooled) | Tirzepatide 5 mg (SURMOUNT-1) | Tirzepatide 10 mg (SURMOUNT-1) | Tirzepatide 15 mg (SURMOUNT-1) |
|---|---|---|---|---|
| Nausea | 43.9% | 24.6% | 33.3% | 31.0% |
| Diarrhea | 29.7% | 18.7% | 21.2% | 23.0% |
| Vomiting | 24.5% | 8.3% | 10.7% | 12.2% |
| Constipation | 24.2% | 16.8% | 17.1% | 11.7% |
Sources: pooled STEP semaglutide rates and SURMOUNT-1 tirzepatide per-dose rates.
The only head-to-head obesity trial is SURMOUNT-5, which ran 72 weeks at maximum-tolerated doses. Its published report gives overall rather than per-symptom figures by arm:
| Measure (SURMOUNT-5, 72 wk, max-tolerated dose) | Tirzepatide | Semaglutide |
|---|---|---|
| Any adverse event | ~77% | ~79% |
| Discontinuation due to adverse events | 6.1% | 8.0% |
| Discontinuation due to GI adverse events | 2.7% | 5.6% |
| Serious adverse events | 4.8% | 3.5% |
| Deaths | 0 | 0 |
In type 2 diabetes, the SURPASS-2 head-to-head compared tirzepatide against semaglutide 1 mg — the diabetes dose, not the 2.4 mg obesity dose — and found broadly overlapping GI rates: nausea 18% (semaglutide) versus 17–22% (tirzepatide across doses), diarrhea 12% versus 13–16%, and discontinuation 4.1% versus 6.0–8.5%.
The differences
Reading the trials together, a few honest distinctions emerge:
- Broadly similar overall. In the fair obesity head-to-head, any-adverse-event rates were close: ~77% (tirzepatide) versus ~79% (semaglutide).
- A modest obesity-trial edge to tirzepatide on stopping. SURMOUNT-5 discontinuation due to adverse events was 6.1% versus 8.0%, and discontinuation specifically for GI effects was 2.7% versus 5.6% — fewer people left the tirzepatide arm because of side effects.
- Serious adverse events ran slightly the other way. They were numerically a touch higher with tirzepatide (4.8% versus 3.5%) — the opposite direction — so there is no clean "one is safer" conclusion.
- The diabetes picture can reverse. In SURPASS-2, the discontinuation pattern can flip at higher tirzepatide doses, and that trial used the lower 1 mg semaglutide diabetes dose, so it does not transfer to obesity dosing.
Net: tolerability is broadly similar between the two, with a modest obesity-trial edge to tirzepatide on discontinuation that does not generalize cleanly across settings.
Why the numbers don't line up cleanly
It is tempting to subtract one column from another and announce a winner. The evidence does not support that, for several reasons:
- Cross-trial comparisons are not apples-to-apples. STEP and SURMOUNT-1 enrolled different populations with different baseline weights, background medications, and titration schedules. Differences between them can reflect the studies as much as the drugs.
- SURPASS-2 used a different dose. It compared tirzepatide against semaglutide 1 mg, the diabetes dose — not the 2.4 mg used for weight management — so its rates should not be read as an obesity comparison.
- SURMOUNT-5 is the only fair obesity head-to-head, and even there the per-symptom breakdown by arm is paywalled and was not verified, which is why this page reports only its overall figures.
- Trial design shapes the discontinuation numbers. SURMOUNT-5 was open-label and titrated to maximum-tolerated dose, both of which influence how many people stop and why.
For how these effects typically resolve over weeks, see how long GLP-1 side effects last, and browse the full comparison hub for related side-by-sides.
Verdict
What this comparison can tell you: both semaglutide and tirzepatide cause the same gastrointestinal class of side effects, mostly mild-to-moderate, worst during dose escalation and easing over time. In the single head-to-head obesity trial, the two were similar overall, with slightly fewer people stopping tirzepatide because of side effects.
What it cannot tell you: which one you, specifically, will tolerate better. Trial averages do not predict individual experience, and the figures here are not a safety ranking — the serious-adverse-event signal actually ran the other way. Choosing between these agents is a decision to make with a prescribing clinician, weighing your history, goals, and how your body responds. This page recommends no drug and no vendor.
Frequently asked questions
Which has fewer side effects, semaglutide or tirzepatide? Neither cleanly wins. In the only fair obesity head-to-head (SURMOUNT-5), overall adverse-event rates were similar — about 77% versus 79% — and slightly fewer people stopped tirzepatide for side effects, but serious adverse events ran a touch higher with tirzepatide. They share the same GI-dominant profile.
Are the side effects of semaglutide and tirzepatide the same kind? Largely, yes. Both act on the GLP-1 receptor, slowing gastric emptying, so both are gastrointestinal-dominant — nausea, vomiting, diarrhea, and constipation lead. Tirzepatide adds GIP activity but its adverse-event profile stays consistent with the class.
Can I compare the trial percentages directly? Not reliably. The semaglutide and tirzepatide rates come from separate trials with different populations and dosing, so subtracting one from the other to claim a tolerability gap is misleading. Only SURMOUNT-5 compared them head-to-head in obesity, and it reports overall, not per-symptom, figures.
Which one should I take? That is a decision for you and a prescribing clinician — this page does not recommend either medicine or any vendor. The evidence shows broadly similar tolerability; your own history and response matter more than trial averages.
How we reviewed this: written from peer-reviewed trial sources, including the pooled STEP semaglutide rates, the SURMOUNT-1 tirzepatide trial, the SURPASS-2 head-to-head in diabetes, and the SURMOUNT-5 head-to-head in obesity. See our editorial and review policy and sourcing standards. Cross-trial comparisons are not apples-to-apples — different populations, baseline weights, background medicines, and doses — so we present the rates side by side without subtracting them, and where head-to-head per-symptom data is paywalled we say so rather than fabricate it.
Every clinical claim above is cited inline to a primary source. See how we review and our sourcing & fact-check standards.